Vol. 26 No. 1 (2022)
REVIEWS

The role and therapeutical potential of melatonin in oncology practice

PDF (Русский)
  • I.I. Eremenko,
  • V.E. Ponomarev,
  • S.B. Polikarpova,
  • E.A. Bogush,
  • V.Yu. Kirsanov,
  • B.A. Zisman,
  • M.M. Davydov
I.I. Eremenko
Sechenov First Moscow State Medical University, Moscow
V.E. Ponomarev
Sechenov First Moscow State Medical University, Moscow
Bio
S.B. Polikarpova
Sechenov First Moscow State Medical University, Moscow
E.A. Bogush
Sechenov First Moscow State Medical University, Moscow
V.Yu. Kirsanov
Sechenov First Moscow State Medical University, Moscow
B.A. Zisman
Sechenov First Moscow State Medical University, Moscow
M.M. Davydov
Sechenov First Moscow State Medical University, Moscow
Мелатонин в онкологической практике
DOI: https://doi.org/10.21688/1681-3472-2022-1-44-54

Published 2022-03-31

Keywords

  • antitumour and accompanying therapy,
  • carcinogenesis,
  • malignancies,
  • melatonin

How to Cite

Eremenko, I., Ponomarev, V., Polikarpova, S., Bogush, E., Kirsanov, V., Zisman, B., & Davydov, M. (2022). The role and therapeutical potential of melatonin in oncology practice. Patologiya Krovoobrashcheniya I Kardiokhirurgiya, 26(1), 44–54. https://doi.org/10.21688/1681-3472-2022-1-44-54

Copyright (c) 2022 Eremenko I.I., Ponomarev V.E., Polikarpova S.B., Bogush E.A., Kirsanov V.Yu., Zisman B.A., Davydov M.M.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

This review describes the available works on four main trends of prospective application and study of melatonin in oncology: the main properties and mechanisms of the antitumor effect of melatonin, melatonin as a direct antitumor agent, melatonin as a drug for the accompanying therapy of psychoemotional disorders and sleep disorders in cancer patients, and melatonin as a drug for the accompanying therapy of chronic pain syndrome in oncology. Currently, researchers focus on fundamental and clinical relationships between circadian rhythms and carcinogenesis, and one of the key problems is the potential of melatonin as an agent capable of interfering with the molecular processes of formation and maintenance of the viability of malignant tumors. An equally important problem is the potential of melatonin in terms of using its physiological properties for the prevention and accompanying therapy of undesirable effects of the main treatment in oncological practice, which is emphasized in this review. The purpose of this review is an unbiased study of the prospects for the multidirectional use of melatonin both as a direct antitumor agent and as a component of complex therapy of concomitant adverse events associated with tumor and the treatment. Based on a detailed analysis of original scientific articles and scientific reviews in the PubMed search system, as well as peer-reviewed Russian journals, authors have made an attempt to characterize the current state of melatonin in oncology based on principles of evidence-based medicine. Authors also suggests and justify key prospects for use of melatonin in oncology practice and the range of studies necessary to clarify its properties and place in the combined therapy of malignant neoplasms.

Received 9 July 2021. Revised 18 August 2021. Accepted 19 August 2021.

Funding: The study did not have sponsorship.

Conflict of interest: Authors declare no conflict of interest.

Contribution of the authors
Conception and study design: I.I. Eremenko, V.E. Ponomarev
Drafting the article: I.I. Eremenko, V.E. Ponomarev, S.B. Polikarpova, E.A. Bogush, V.Yu. Kirsanov, B.A. Zisman, M.M. Davydov
Critical revision of the article: I.I. Eremenko, V.E. Ponomarev
Final approval of the version to be published: I.I. Eremenko, V.E. Ponomarev, S.B. Polikarpova, E.A. Bogush, V.Yu. Kirsanov, B.A. Zisman, M.M. Davydov

PDF (Русский)

References

  1. Cемиглазова Т.Ю., Осипов М.А., Новик А.В., Клименко В.В., Анисимов В.Н. Перспективы использования мелатонина в клинической онкологии. Злокачественные опухоли. 2016;(4):21-29. [Semiglazova T.U., Osipov M.A., Novik A.V., Klimenko V.V., Anisimov V.N. Perspectives of melatonin use in clinical oncology. Malignant tumours. 2016;(4):21-29. (In Russ.)] https://doi.org/10.18027/2224-5057-2016-4-21-29
  2. Alghamdi B.S. The neuroprotective role of melatonin in neurological disorders. J Neurosci Res. 2018;96(7):1136-1149. PMID: 29498103; PMCID: PMC6001545. https://doi.org/10.1002/jnr.24220
  3. Xie Sh., Fan W., He H., Huang F. Role of melatonin in the regulation of pain. J Pain Res. 2020;13:331-343. PMID: 32104055; PMCID: PMC7012243. https://doi.org/10.2147/JPR.S228577
  4. Talib W.H. Melatonin and cancer hallmarks. Molecules. 2018;23(3):518. PMID: 29495398; PMCID: PMC6017729. https://doi.org/10.3390/molecules23030518
  5. Zhao D., Yu Y., Shen Y., Liu Q., Zhao Zh., Sharma R., Reiter R.J. Melatonin synthesis and function: evolutionary history in animals and plants. Front Endocrinol. 2019;10:249. PMID: 31057485; PMCID: PMC6481276. https://doi.org/10.3389/fendo.2019.00249
  6. Райхлин Н.Т., Кветной И.М., Тюрин Е.С. Мелатонин в сыворотке крови онкологических пациентов. Клиническая медицина. 1980;58(5):77-79. [Raikhlin N.T., Kvetnoi I.M., Tyurin E.S. Melatonin in the blood serum of oncological patients. Klinicheskaia meditsina = Clinical Medicine (Russian Journal). 1980;58(5):77-79. (In Russ.)]
  7. Cipolla-Neto J., Amaral F.G. Melatonin as a hormone: new physiological and clinical insights. Endocr Rev. 2018;39(6):990-1028. PMID: 30215696. https://doi.org/10.1210/er.2018-00084
  8. Hardeland R. Recent findings in melatonin research and their relevance to the CNS. Cent Nerv Syst Agents Med Chem. 2018;18(2):102-114. PMID: 29848280. https://doi.org/10.2174/1871524918666180531083944
  9. Liu J., Clough Sh.J., Hutchinson A.J., Adamah-Biassi E.B., Popovska-Gorevski M., Dubocovich M.L. MT1 and MT2 melatonin receptors: a therapeutic perspective. Annu Rev Pharmacol Toxicol. 2016;56:361-383. PMID: 26514204; PMCID: PMC5091650. https://doi.org/10.1146/annurev-pharmtox-010814-124742
  10. Emet M., Ozcan H., Ozel L., Yayla M., Halici Z., Hacimuftuoglu A. A review of melatonin, its receptors and drugs. Eur J Med. 2016;48(2):135-141. PMID: 27551178; PMCID: PMC4970552. https://doi.org/10.5152/eurasianjmed.2015.0267
  11. Stojkovic K., Wing S.S., Cermakian N. A central role for ubiquitination within a circadian clock protein modification code. Front Mol Neurosci. 2014;7:69. PMID: 25147498; PMCID: PMC4124793. https://doi.org/10.3389/fnmol.2014.00069
  12. Vriend J., Reiter R.J. Melatonin feedback on clock genes: a theory involving the proteasome. J Pineal Res. 2015;58(1):1-11. PMID: 25369242. https://doi.org/10.1111/jpi.12189
  13. Zhang L., He Yu., Wu X., Zhao G., Zhang K., Yang Ch.S., Reiter R.J., Zhang J. Melatonin and (-)-Epigallocatechin-3-Gallate: partners in fighting cancer. Cells. 2019;8(7):745. PMID: 31331008; PMCID: PMC6678710. https://doi.org/10.3390/cells8070745
  14. Beker M.C., Caglayan B., Caglayan A.B., Kelestemur T., Yalcin E., Caglayan A., Kilic U., Baykal A.T., Reiter R.J., Kilic E. Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway components and cellular survival. Sci Rep. 2019;9(1):19082. PMID: 31836786; PMCID: PMC6910929. https://doi.org/10.1038/s41598-019-55663-0
  15. Chen J., Wang A., Chen Q. SirT3 and p53 deacetylation in aging and cancer. J Cell Physiol. 2017;232(9):2308-2311. PMID: 27791271. https://doi.org/10.1002/jcp.25669
  16. Reiter R.J., Tan D.X., Rosales-Corral S., Galano A., Jou M.-J., Acuna-Castroviejo D. Melatonin mitigates mitochondrial meltdown: interactions with SIRT3. Int J Mol Sci. 2018;19(8):2439. PMID: 30126181; PMCID: PMC6121285. https://doi.org/10.3390/ijms19082439
  17. Li Y., Li Sh., Zhou Y., Meng X., Zhang J.-J., Xu D.-P., Li H.-B. Melatonin for the prevention and treatment of cancer. Oncotarget. 2017;8(24):39896-39921. PMID: 28415828; PMCID: PMC5503661. https://doi.org/10.18632/oncotarget.16379
  18. Sohn E.J., Won G., Lee J., Lee S., Kim S.-H. Upregulation of miRNA3195 and miRNA374b mediates the anti-angiogenic properties of melatonin in hypoxic PC-3 prostate cancer cells. J Cancer. 2015;6(1):19-28. PMID: 25553085; PMCID: PMC4278911. https://doi.org/10.7150/jca.9591
  19. Prieto-Domínguez N., Méndez-Blanco C., Carbajo-Pescador S., Fondevila F., García-Palomo A., González-Gallego J., Mauriz J.L. Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy. Oncotarget. 2017;8(53):91402-91414. PMID: 29207653; PMCID: PMC5710933. https://doi.org/10.18632/oncotarget.20592
  20. Rondanelli M., Faliva M.A., Perna S., Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res. 2013;25(5):499-510. PMID: 24046037; PMCID: PMC3788186. https://doi.org/10.1007/s40520-013-0118-6
  21. Попков В.М. Прогностическое значение молекулярных маркеров при опухолях предстательной железы. Медицинская наука и образование Урала. 2010;(2):30-34. [Popkov V.M. Prognostic importance of molecular markers at prostates cancer diseases. Medical Science and Education of Ural. 2010;(2):30-34. (In Russ.)]
  22. Zharinov G.M., Bogomolov O.A., Chepurnaya I.V., Neklasova N.Yu., Anisimov V.N. Melatonin increases overall survival of prostate cancer patients with poor prognosis after combined hormone radiation treatment. Oncotarget. 2020;11(41):3723-3729. PMID: 33110479; PMCID: PMC7566809. https://doi.org/10.18632/oncotarget.27757
  23. Parent M.-É., El-Zein M., Rousseau M.-C., Pintos J., Siemiatycki J. Night work and the risk of cancer among men. Am J Epidemiol. 2012;176(9):751-759. PMID: 23035019. https://doi.org/10.1093/aje/kws318
  24. Rosen G., Brand S.R. Sleep in children with cancer: case review of 70 children evaluated in a comprehensive pediatric sleep center. Support Care Cancer. 2011;19(7):985-994. PMID: 20517621. https://doi.org/10.1007/s00520-010-0921-y
  25. Плисс М.М. Мелатонин в комплексном лечении больных колоректальным раком. Вопросы онкологии. 2016;62(3):413-417. [Pliss М.М. Melatonin in complex treatment for colorectal cancer patients. Problems in Oncology. 2016;62(3):413-417. (In Russ.)]
  26. Ермаченков М.Н., Гуляев А.В., Анисимов В.Н. Мелатонин и рак толстой кишки: повышение эффективности стандартного лечения. Вестник Северо-Западного государственного медицинского университета им. И.И. Мечникова. 2012;4(1):78-83. [Ermachenkov M.N., Guliaev A.V., Anisimov V.N. Melatonin and colorectal cancer: the rise of standart treatment efficacy. Herald of North-Western State Medical University named after I.I. Mechnikov. 2012;4(1):78-83. (In Russ.)]
  27. Ермаченков М.Н., Гуляев А.В., Анисимов В.Н., Арутюнян А.В., Милютина Ю.П. Эффективность применения мелатонина при раке желудка. Врач-аспирант. 2012;51(2.3):389-395. [Ermachenkov M.N., Guliaev A.V., Anisimov V.N., Arutyunyan A.V., Milyutina Yu.P. Efficacy of melatonin treatment in stomach cancer patients. Postgraduate Doctor Journal. 2012;51(2.3):389-395. (In Russ.)]
  28. Xu J., Huang L., Sun G.-P. Urinary 6-sulfatoxymelatonin level and breast cancer risk: systematic review and meta-analysis. Sci Rep. 2017;7(1):5353. PMID: 28706222; PMCID: PMC5509698. https://doi.org/10.1038/s41598-017-05752-9
  29. Seely D., Wu P., Fritz H., Kennedy D.A., Tsui T., Seely A.J.E., Mills E. Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials. Integr Cancer Ther. 2012;11(4):293-303. PMID: 22019490. https://doi.org/10.1177/1534735411425484
  30. Mills E., Wu P., Seely D., Guyatt G. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39(4):360-366. PMID: 16207291. https://doi.org/10.1111/j.1600-079X.2005.00258.x
  31. Wang Y.-M., Jin B.-Zh., Ai F., Duan Ch.-H., Lu Y.-Z., Dong T.-F., Fu Q.-L. The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials. Cancer Chemother Pharmacol. 2012;69(5):1213-1220. PMID: 22271210. https://doi.org/10.1007/s00280-012-1828-8
  32. Kouhi Habibi N., Shabestani Monfared A., Ebrahimnejad Gorji K., Karimi M., Moghadamnia A.A., Tourani M., Borzoueisileh S., Niksirat F. The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial. Clin Transl Oncol. 2019;21(6):745-752. PMID: 30421178. https://doi.org/10.1007/s12094-018-1977-2
  33. Ben-David M.A., Elkayam R., Gelernter I., Pfeffer R.M. Melatonin for prevention of breast radiation dermatitis: a phase II, prospective, double-blind randomized trial. Isr Med Assoc J. 2016;18(3-4):188-192. PMID: 27228641.
  34. Barreto F.S., Chaves Filho A.J.M., de Araújo M.C.C.R., de Moraes M.O., de Moraes M.E.A., Maes M., de Lucena D.F., Macedo D.S. Tryptophan catabolites along the indoleamine 2,3-dioxygenase pathway as a biological link between depression and cancer. Behav Pharmacol. 2018;29(2 and 3-Spec Issue):165-180. PMID: 29543650. https://doi.org/10.1097/FBP.0000000000000384
  35. Rondanelli M., Faliva M.A., Perna S., Antoniello N. Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks. Aging Clin Exp Res. 2013;25(5):499-510. PMID: 24046037; PMCID: PMC3788186. https://doi.org/10.1007/s40520-013-0118-6
  36. Chen W.Y., Giobbie-Hurder A., Gantman K., Savoie J., Scheib R., Parker L.M., Schernhammer E.S. A randomized, placebo-controlled trial of melatonin on breast cancer survivors: impact on sleep, mood, and hot flashes. Breast Cancer Res Treat. 2014;145(2):381-388. PMID: 24718775; PMCID: PMC4060962. https://doi.org/10.1007/s10549-014-2944-4
  37. Hansen M.V., Andersen L.T., Madsen M.T., Hageman I., Rasmussen L.S., Bokmand S., Rosenberg J., Gögenur I. Effect of melatonin on depressive symptoms and anxiety in patients undergoing breast cancer surgery: a randomized, double-blind, placebo-controlled trial. Breast Cancer Res Treat. 2014;145(3):683-695. PMID: 24756186. https://doi.org/10.1007/s10549-014-2962-2
  38. Hansen M.V., Halladin N.L., Rosenberg J., Gögenur I., Møller A.M. Melatonin for pre- and postoperative anxiety in adults. Cochrane Database Syst Rev. 2015;2015(4):CD009861. PMID: 25856551; PMCID: PMC6464333. https://doi.org/10.1002/14651858.CD009861.pub2
  39. Chang W.-P., Lin Ch.-Ch. Relationships of salivary cortisol and melatonin rhythms to sleep quality, emotion, and fatigue levels in patients with newly diagnosed lung cancer. Eur J Oncol Nurs. 2017;29:79-84. PMID: 28720269. https://doi.org/10.1016/j.ejon.2017.05.008
  40. Bjørklund G., Dadar M., Aaseth J., Chirumbolo S., Pen J.J. Cancer-associated cachexia, reactive oxygen species and nutrition therapy. Curr Med Chem. 2019;26(31):5728-5744. PMID: 29956613. https://doi.org/10.2174/0929867325666180629123817
  41. Del Fabbro E., Dev R., Hui D., Palmer L., Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31(10):1271-1276. PMID: 23439759; PMCID: PMC3607670. https://doi.org/10.1200/JCO.2012.43.6766
  42. Caraceni A., Shkodra M. Cancer pain assessment and classification. Cancers (Basel). 2019;11(4):510. PMID: 30974857; PMCID: PMC6521068. https://doi.org/10.3390/cancers11040510
  43. Oh S.N., Myung S.-K., Jho H.J. Analgesic efficacy of melatonin: a meta-analysis of randomized, double-blind, placebo-controlled trials. J Clin Med. 2020;9(5):1553. PMID: 32455582; PMCID: PMC7291209. https://doi.org/10.3390/jcm9051553
  44. Palmer A.C.S., Souza A., Dos Santos V.S., Cavalheiro J.A.C., Schuh F., Zucatto A.E., Biazus J.V., Torres I.L.D.S., Fregni F., Caumo W. The effects of melatonin on the descending pain inhibitory system and neural plasticity markers in breast cancer patients receiving chemotherapy: randomized, double-blinded, placebo-controlled trial. Front Pharmacol. 2019;10:1382. PMID: 31824318; PMCID: PMC6883914. https://doi.org/10.3389/fphar.2019.01382
  45. Galley H.F., McCormick B., Wilson K.L., Lowes D.A., Colvin L., Torsney C. Melatonin limits paclitaxel-induced mitochondrial dysfunction in vitro and protects against paclitaxel-induced neuropathic pain in the rat. J Pineal Res. 2017;63(4):e12444. PMID: 28833461; PMCID: PMC5656911. https://doi.org/10.1111/jpi.12444
  46. Ertilav K., Nazıroğlu M., Ataizi Z.S., Yıldızhan K. Melatonin and selenium suppress docetaxel-induced TRPV1 activation, neuropathic pain and oxidative neurotoxicity in mice. Biol Trace Elem Res. 2021;199(4):1469-1487. PMID: 32578137. https://doi.org/10.1007/s12011-020-02250-4
  47. Areti A., Komirishetty P., Akuthota M., Malik R.A., Kumar A. Melatonin prevents mitochondrial dysfunction and promotes neuroprotection by inducing autophagy during oxaliplatin-evoked peripheral neuropathy. J Pineal Res. 2017;62(3). PMID: 28118492. https://doi.org/10.1111/jpi.12393
  48. Chen I.-J., Yang Ch.-P., Lin Sh.-H., Lai Ch.-M., Wong Ch.-Sh. The circadian hormone melatonin inhibits morphine-induced tolerance and inflammation via the activation of antioxidative enzymes. Antioxidants (Basel). 2020;9(9):780. PMID: 32842597; PMCID: PMC7555201. https://doi.org/10.3390/antiox9090780
  49. Hemati K., Pourhanifeh M.H., Dehdashtian E., Fatemi I., Mehrzadi S., Reiter R.J., Hosseinzadeh A. Melatonin and morphine: potential beneficial effects of co-use. Fundam Clin Pharmacol. 2021;35(1):25-39. PMID: 32415694. https://doi.org/10.1111/fcp.12566
  50. Farhood B., Goradel N.H., Mortezaee K., Khanlarkhani N., Salehi E., Nashtaei M.S., Mirtavoos-Mahyari H., Motevaseli E., Shabeeb D., Musa A.E., Najafi M. Melatonin as an adjuvant in radiotherapy for radioprotection and radiosensitization. Clin Transl Oncol. 2019;21(3):268-279. PMID: 30136132. https://doi.org/10.1007/s12094-018-1934-0
  51. Musa A.E., Shabeeb D., Alhilfi H.S.Q. Protective effect of melatonin against radiotherapy-induced small intestinal oxidative stress: biochemical evaluation. Medicina (Kaunas). 2019;55(6):308. PMID: 31242652; PMCID: PMC6631393. https://doi.org/10.3390/medicina55060308
  52. Amini P., Mirtavoos-Mahyari H., Motevaseli E., Shabeeb D., Musa A.E., Cheki M., Farhood B., Yahyapour R., Shirazi A., Goushbolagh N.A., Najafi M. Mechanisms for radioprotection by melatonin; Can it be used as a radiation countermeasure? Curr Mol Pharmacol. 2019;12(1):2-11. PMID: 30073934. https://doi.org/10.2174/1874467211666180802164449
  53. Mihandoost E., Shirazi A., Mahdavi S.R., Aliasgharzadeh A. Can melatonin help us in radiation oncology treatments? Biomed Res Int. 2014;2014:578137. PMID: 24900972; PMCID: PMC4037598. https://doi.org/10.1155/2014/578137
  54. Onseng K., Johns N.P., Khuayjarernpanishk T., Subongkot S., Priprem A., Hurst C., Johns J. Beneficial effects of adjuvant melatonin in minimizing oral mucositis complications in head and neck cancer patients receiving concurrent chemoradiation. J Altern Complement Med. 2017;23(12):957-963. PMID: 28657801. https://doi.org/10.1089/acm.2017.0081
  55. Elsabagh H.H., Moussa E., Mahmoud S.A., Elsaka R.O., Abdelrahman H. Efficacy of Melatonin in prevention of radiation-induced oral mucositis: A randomized clinical trial. Oral Diseases. 2020;26(3):566-572. PMID: 31869853. https://doi.org/10.1111/odi.13265
  56. Bonmati-Carrion M.-A., Tomas-Loba A. Melatonin and cancer: a polyhedral network where the source matters. Antioxidants (Basel). 2021;10(2):210. PMID: 33535472; PMCID: PMC7912767. https://doi.org/10.3390/antiox10020210
  57. Fernández-Palanca P., Méndez-Blanco C., Fondevila F., Tuñón M.J., Reiter R.J., Mauriz J.L., González-Gallego J. Melatonin as an antitumor agent against liver cancer: an updated systematic review. Antioxidants (Basel). 2021;10(1):103. PMID: 33445767; PMCID: PMC7828223. https://doi.org/10.3390/antiox10010103
  58. González A., Alonso-González C., González-González A., Menéndez-Menéndez J., Cos S., Martínez-Campa C. Melatonin as an adjuvant to antiangiogenic cancer treatments. Cancers. 2021;13(13):3263. PMID: 34209857; PMCID: PMC8268559. https://doi.org/10.3390/cancers13133263
  59. Laborda-Illanes A., Sánchez-Alcoholado L., Boutriq S., Plaza-Andrades I., Peralta-Linero J., Alba E., González-González A., Queipo-Ortuño M.I. A new paradigm in the relationship between melatonin and breast cancer: gut microbiota identified as a potential regulatory agent. Cancers. 2021;13(13):3141. PMID: 34201776; PMCID: PMC8269379. https://doi.org/10.3390/cancers13133141